Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Total Liabilities of $20.4 million for Q1 2026, up 11.96% year-over-year from $18.3 million in Q1 2025, and down 25.36% quarter-over-quarter from $27.4 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $20.4 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 11.96% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $20.4 million (up 11.96% YoY), while the FY2025 annual figure was $27.4 million, down 5.14% from the prior year.
- Total Liabilities for Q1 2026 stood at $20.4 million, down from $27.4 million in the prior quarter.
- The five-year high for Total Liabilities was $93.0 million in Q1 2024, with the low at $18.3 million in Q1 2025.
- The 5-year median for Total Liabilities is $37.4 million (2022), against an average of $45.9 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 191.7% in 2022, then slumped 80.37% in 2025.
- Amylyx Pharmaceuticals' Total Liabilities stood at $50.8 million in 2022, then jumped by 65.25% to $84.0 million in 2023, then slumped by 65.64% to $28.9 million in 2024, then fell by 5.14% to $27.4 million in 2025, then dropped by 25.36% to $20.4 million in 2026.
- Business Quant data shows AMLX's Total Liabilities at $20.4 million in Q1 2026, $27.4 million in Q4 2025, and $30.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 2.12 Bn |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | 25.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.40 Mn |
| Mar 31, 2026 | 20.44 Mn |
| Dec 31, 2025 | 27.39 Mn |
| Sep 30, 2025 | 30.75 Mn |
| Jun 30, 2025 | 26.72 Mn |
| Mar 31, 2025 | 18.26 Mn |
| Dec 31, 2024 | 28.87 Mn |
| Sep 30, 2024 | 54.51 Mn |
| Jun 30, 2024 | 70.85 Mn |
| Mar 31, 2024 | 93.02 Mn |
| Dec 31, 2023 | 84.02 Mn |
| Sep 30, 2023 | 48.18 Mn |
| Jun 30, 2023 | 67.22 Mn |
| Mar 31, 2023 | 55.31 Mn |
| Dec 31, 2022 | 50.85 Mn |
| Sep 30, 2022 | 37.42 Mn |
| Jun 30, 2022 | 32.45 Mn |
| Mar 31, 2022 | 33.49 Mn |
| Dec 31, 2021 | 17.43 Mn |